Recent News

SciFluor News

SciFluor Announces Positive Top-Line Results of Phase 1/2 Study of SF0166 Eye Drops to Treat Wet Age-Related Macular Degeneration
read more >

SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases
read more >

SciFluor Announces Positive Results of Phase 1/2 Study of SF0166 Topical Ophthalmic Solution in Diabetic Macular Edema Patients
read more >


SciFluor Life Sciences is a drug discovery company developing a broad portfolio of differentiated therapeutics to treat various diseases.

SciFluor is focused on creating proprietary best-in-class drugs based on well-understood pathways in areas of significant medical need such as ophthalmology, fibrosis and neurology. Our lead clinical drug candidate, SF0166, is an eye drop therapeutic for treating back-of-the-eye diseases.